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The association between calcium dobesilate and 
pancytopenia in type 2 diabetes: A case report
Tip 2 diyabet hastasında kalsiyum dobesilat ile pansitopeni ilişkisi: 
Bir olgu sunumu
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To the Editor,
Diabetic patients with polypharmacy are prone 
to unexpected drug side effects. Chronic venous 
insufficiency (CVI) is frequent in the type 2 diabetic 
population due to advanced age and obesity, and is 
associated with increased podiatric risk [1,2]. 
Calcium dobesilate (CaD) is a widely prescribed 
veno-tonic drug for CVI, diabetic retinopathy, and 
the symptoms of hemorrhoid attacks [3]. To date, 
all published cases of CaD-induced agranulocytosis 
are >60 years of age [4,5-10]. Ibanez et al. recently 
reported that CaD was strongly associated with the 
risk of agranulocytosis [10]. Herein we present a 
case of CaD-induced pancytopenia in an 80-year-
old male diabetic patient. We had written informed 
consent from the patient.
The patient presented to our hospital with a fever 
of 39°C. He had been type 2 diabetic for 25 years and 
was treated with repaglinide 2mg b.i.d. and insulin 
glargine 20U o.p.d. He was also hypertensive and 
dyslipidemic, and was using atenolol 50 mg/day, 
lisinopril 20 mg/day, amlodipine 10 mg/day, 
hydrochlorothiazide 50 mg/day, atorvastatin 10 mg/
day, and acetylsalicylic acid 100 mg/day for last 8 
years. Six weeks before he presented to hospital he 
was diagnosed with CVI and CaD 500 mg b.i.d. was 
started following a cardiovascular surgery 
consultation. 
After 6 weeks of the treatment leukopenia, 
thrombocytopenia, and anemia were observed. His 
hematoxylin-eosin-stained blood smear confirmed 
markedly decreased platelet and leucocyte counts, 
accompanied by normochromic normocytic red 
cells (Table). CaD treatment was withdrawn 
because of the potential side effects. On physical 
examination the patient did not have organomegaly 
or palpable lymph nodes. His iron, ferritin, vitamin 
B12, and folate levels, and reticulocyte count were 
within normal limits, and ANA (anti nuclear 
antibody) and anti-double stranded DNA test results 
were negative. The patient was hospitalized and 
was prescribed intravenous ceftriaxone 2 g/day and 
clarithromycin 400 mg/day, following the diagnosis of pneumonia. The patient was discharged after 1 
week of hospitalization with improved hemogram 
results (Table 1).
Three months after discharge he was again 
admitted to our hospital with a fever of 38.6°C. It 
was learned that he again had started taking CaD. 
Pancytopenia was diagnosed, CaD was withdrawn, 
and the same intravenous antibiotic therapy was 
started again. Bone marrow biopsy and aspiration 
were performed from the iliac crest. Wright staining 
of the bone marrow aspiration smear microscopically 
showed normal erythroid and myeloid cell lines. 
The patient was discharged with a normal blood 
count after 1 week.
In conclusion, we want to emphasize the 
potential for serious side effects that affect the 
immune system in polypharmacy diabetic patients, 
such as granulocytopenia, and the importance of 
pharmacovigilance in patients with chronic diseases 
and the risk of comorbidity.
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Table 1. The patient’s complete blood count during the follow-up peri-
od, with and without medication
  Before  6 Weeks After  1 Week After  3 months later,
 CaD  CaD  Hospitalization  again  with 
       CaD  use
WBC  (×109 L-1) 6.2  2.4  5.93  4.0
Neutrophils (%)  67  34  70  74
Lymphocytes (%)  20  48  21  16
Monocytes (%)   
Basophiles (%)  9  16  7  6
Eosinophils (%)  1  1  1  2
 3  1  1  2
Hb (g dL-1) 13.1  10.3  11.4  10.8
Platelet (×109 L-1) 219  122  235  101
Platelet (×109 L-1) 219  122  235  101
CaD: Calcium dobesilate; WBC: white blood cells; Hb: hemoglobin